Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
10.08
-0.24 (-2.33%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Fennec Pharmaceuticals Revenue
Fennec Pharmaceuticals had revenue of $17.87M in the quarter ending June 30, 2026, with 85.18% growth. This brings the company's total for the last twelve months to $59.22M, up 77.83% year-over-year. In the year 2025, Fennec Pharmaceuticals had annual revenue of $44.64M, down -6.09%. That makes Fennec Pharmaceuticals the 26,668th largest company in the world by revenue and 3,651st in the United States.
Revenue (ttm)
$59.22M
Revenue Growth
+77.83%
P/S Ratio
5.97
Revenue / Employee
$1,692,029
Employees
35
Market Cap
353.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.64M | -2.90M | -6.09% |
| Dec 31, 2024 | 47.54M | 26.29M | 123.69% |
| Dec 31, 2023 | 21.25M | 19.72M | 1,284.50% |
| Dec 31, 2022 | 1.54M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Editas Medicine | 47.01M |
| vTv Therapeutics | 36.84M |
| C4 Therapeutics | 35.04M |
| Scribe Therapeutics | 33.30M |
| Prelude Therapeutics | 22.42M |
| Capricor Therapeutics | 11.13M |
FENC News
- 5 weeks ago - Fennec presents results from STS-J01 clinical trial evaluating Pedmark - TheFly
- 5 weeks ago - Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 - GlobeNewsWire
- 5 weeks ago - Fennec Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Fennec Pharmaceuticals Slides: Corporate presentation - Filings
- 2 months ago - Fennec price target raised to $16 from $13 at Wedbush - TheFly
- 2 months ago - Fennec price target raised to $18 from $16 at B. Riley - TheFly
- 2 months ago - Fennec Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Fennec Pharmaceuticals Earnings release: Q2 2026 - Filings